Putting our science into action

Our research programs

Trem-cel + Mylotarg

Trem-cel (tremtelectogene empogeditemcel) is a shielded stem cell transplant in development for patients with AML and MDS, in which healthy transplant donor cells are genetically engineered by removing CD33. Patients are then treated post-transplant with Mylotarg™ to selectively kill cancer cells and avoid toxicity.

VCAR33

We are developing a highly potent CAR-T cell therapy, the first healthy donor HLA-matched CD33-directed CAR-T in the clinic for AML, which could be potentially curative.

Trem-cel+VCAR33 Treatment System

This Treatment System combines trem-cel and VCAR33 representing another significant synergistic treatment option that could potentially cure AML. A feature of this Treatment System is that it uses the same allogeneic source of cells for both the shielded transplant and CAR-T cells.

VADC45

VADC45 is a CD45-directed ADC. CD45 is an excellent target for a variety of blood cancers with clinical proof-of-concept and the potential to treat other diseases including hematologic malignancies, sickle cell, and autoimmune disorders.

CD33-CLL1 Multiplex Treatment System

This Treatment System offers a promising new approach to treating patients with AML. It would combine a shielded transplant removing multiple surface targets with a dual-specific CAR-T that combines two constructs that target the two most promising antigens in AML aiming for deeper and more durable responses in relapsed/refractory AML.

Discovery platform

We are conducting ongoing discovery efforts in commonly transplanted hematologic malignancies.